Progestin therapy for endometrial cancer: The potential of fourth-generation progestin (Review)

Kouji Banno, Iori Kisu, Megumi Yanokura, Kosuke Tsuji, Kenta Masuda, Arisa Ueki, Yusuke Kobayashi, Wataru Yamagami, Hiroyuki Nomura, Nobuyuki Susumu, Daisuke Aoki

研究成果: Article

26 引用 (Scopus)

抄録

Progestin preparations are made of synthetic progesterone and have often been used for hormone therapy in gynecological patients with endometriosis or endometrial cancer. Hormone therapy using progestin is considered to be one of the effective means of treatment particularly when dealing with endometrial cancer (an estrogen-dependent tumor). Numerous reports have been published concerning its efficacy in advanced or recurrent cases of atypical endometrial hyperplasia or endometrial cancer. Dienogest has been developed as a fourth-generation progestin for hormone therapy for endometriosis that can be used with high safety for long periods of time. In Japan, dienogest has been recommended as a first-line drug for endometriosis-associated pain. However, its antitumor activity has also been attracting close attention following a report that this drug suppressed the proliferation in vitro of endometrial cancer-derived cell lines which failed to respond to other progestins such as medroxyprogesterine acetate (MPA). The mechanism for antitumor activity of dienogest is considered to differ from the mechanism for antitumor activity of conventional progestin preparations used for treatment of endometrial cancer. This drug is expected to be clinically applicable as a new drug for the treatment of endometrial cancer.

元の言語English
ページ(範囲)1755-1762
ページ数8
ジャーナルInternational Journal of Oncology
40
発行部数6
DOI
出版物ステータスPublished - 2012 6

Fingerprint

dienogest
Progestins
Endometrial Neoplasms
Endometriosis
Hormones
Pharmaceutical Preparations
Therapeutics
Endometrial Hyperplasia
Progesterone
Japan
Estrogens
Acetates
Safety
Pain
Cell Line
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

これを引用

Progestin therapy for endometrial cancer : The potential of fourth-generation progestin (Review). / Banno, Kouji; Kisu, Iori; Yanokura, Megumi; Tsuji, Kosuke; Masuda, Kenta; Ueki, Arisa; Kobayashi, Yusuke; Yamagami, Wataru; Nomura, Hiroyuki; Susumu, Nobuyuki; Aoki, Daisuke.

:: International Journal of Oncology, 巻 40, 番号 6, 06.2012, p. 1755-1762.

研究成果: Article

Banno, Kouji ; Kisu, Iori ; Yanokura, Megumi ; Tsuji, Kosuke ; Masuda, Kenta ; Ueki, Arisa ; Kobayashi, Yusuke ; Yamagami, Wataru ; Nomura, Hiroyuki ; Susumu, Nobuyuki ; Aoki, Daisuke. / Progestin therapy for endometrial cancer : The potential of fourth-generation progestin (Review). :: International Journal of Oncology. 2012 ; 巻 40, 番号 6. pp. 1755-1762.
@article{e8c77055aa8d4be0a4d9457ccd3f1719,
title = "Progestin therapy for endometrial cancer: The potential of fourth-generation progestin (Review)",
abstract = "Progestin preparations are made of synthetic progesterone and have often been used for hormone therapy in gynecological patients with endometriosis or endometrial cancer. Hormone therapy using progestin is considered to be one of the effective means of treatment particularly when dealing with endometrial cancer (an estrogen-dependent tumor). Numerous reports have been published concerning its efficacy in advanced or recurrent cases of atypical endometrial hyperplasia or endometrial cancer. Dienogest has been developed as a fourth-generation progestin for hormone therapy for endometriosis that can be used with high safety for long periods of time. In Japan, dienogest has been recommended as a first-line drug for endometriosis-associated pain. However, its antitumor activity has also been attracting close attention following a report that this drug suppressed the proliferation in vitro of endometrial cancer-derived cell lines which failed to respond to other progestins such as medroxyprogesterine acetate (MPA). The mechanism for antitumor activity of dienogest is considered to differ from the mechanism for antitumor activity of conventional progestin preparations used for treatment of endometrial cancer. This drug is expected to be clinically applicable as a new drug for the treatment of endometrial cancer.",
keywords = "Dienogest, Endometrial cancer, Medroxyprogesterone acetate, Progesterone receptor, Progestin",
author = "Kouji Banno and Iori Kisu and Megumi Yanokura and Kosuke Tsuji and Kenta Masuda and Arisa Ueki and Yusuke Kobayashi and Wataru Yamagami and Hiroyuki Nomura and Nobuyuki Susumu and Daisuke Aoki",
year = "2012",
month = "6",
doi = "10.3892/ijo.2012.1384",
language = "English",
volume = "40",
pages = "1755--1762",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Progestin therapy for endometrial cancer

T2 - The potential of fourth-generation progestin (Review)

AU - Banno, Kouji

AU - Kisu, Iori

AU - Yanokura, Megumi

AU - Tsuji, Kosuke

AU - Masuda, Kenta

AU - Ueki, Arisa

AU - Kobayashi, Yusuke

AU - Yamagami, Wataru

AU - Nomura, Hiroyuki

AU - Susumu, Nobuyuki

AU - Aoki, Daisuke

PY - 2012/6

Y1 - 2012/6

N2 - Progestin preparations are made of synthetic progesterone and have often been used for hormone therapy in gynecological patients with endometriosis or endometrial cancer. Hormone therapy using progestin is considered to be one of the effective means of treatment particularly when dealing with endometrial cancer (an estrogen-dependent tumor). Numerous reports have been published concerning its efficacy in advanced or recurrent cases of atypical endometrial hyperplasia or endometrial cancer. Dienogest has been developed as a fourth-generation progestin for hormone therapy for endometriosis that can be used with high safety for long periods of time. In Japan, dienogest has been recommended as a first-line drug for endometriosis-associated pain. However, its antitumor activity has also been attracting close attention following a report that this drug suppressed the proliferation in vitro of endometrial cancer-derived cell lines which failed to respond to other progestins such as medroxyprogesterine acetate (MPA). The mechanism for antitumor activity of dienogest is considered to differ from the mechanism for antitumor activity of conventional progestin preparations used for treatment of endometrial cancer. This drug is expected to be clinically applicable as a new drug for the treatment of endometrial cancer.

AB - Progestin preparations are made of synthetic progesterone and have often been used for hormone therapy in gynecological patients with endometriosis or endometrial cancer. Hormone therapy using progestin is considered to be one of the effective means of treatment particularly when dealing with endometrial cancer (an estrogen-dependent tumor). Numerous reports have been published concerning its efficacy in advanced or recurrent cases of atypical endometrial hyperplasia or endometrial cancer. Dienogest has been developed as a fourth-generation progestin for hormone therapy for endometriosis that can be used with high safety for long periods of time. In Japan, dienogest has been recommended as a first-line drug for endometriosis-associated pain. However, its antitumor activity has also been attracting close attention following a report that this drug suppressed the proliferation in vitro of endometrial cancer-derived cell lines which failed to respond to other progestins such as medroxyprogesterine acetate (MPA). The mechanism for antitumor activity of dienogest is considered to differ from the mechanism for antitumor activity of conventional progestin preparations used for treatment of endometrial cancer. This drug is expected to be clinically applicable as a new drug for the treatment of endometrial cancer.

KW - Dienogest

KW - Endometrial cancer

KW - Medroxyprogesterone acetate

KW - Progesterone receptor

KW - Progestin

UR - http://www.scopus.com/inward/record.url?scp=84861777930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861777930&partnerID=8YFLogxK

U2 - 10.3892/ijo.2012.1384

DO - 10.3892/ijo.2012.1384

M3 - Article

C2 - 22366992

AN - SCOPUS:84861777930

VL - 40

SP - 1755

EP - 1762

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -